Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2007

01.03.2007

Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy

verfasst von: Peter Kornprat, MD, William R. Jarnagin, MD, FACS, Mithat Gonen, PhD, Ronald P. DeMatteo, MD, FACS, Yuman Fong, MD, FACS, Leslie H. Blumgart, MD, FACS, FRCS, Michael D’Angelica, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatic resection is generally accepted as the only potential for long-term survival in patients with colorectal metastases confined to the liver. Despite an unknown benefit, hepatic resection is playing an increasing role in patients with extensive disease.

Methods

A retrospective review of a prospectively maintained hepatobiliary surgical database was carried out. Outcome after hepatectomy for four or more colorectal hepatic metastases was reviewed.

Results

Between 1998 and 2002, out of a total of 584 patients, 98 (17%) with four or more colorectal hepatic metastases were resected. Actuarial 5-year survival was 33% for the entire group, with seven actual 5-year survivors. There were no perioperative deaths, and the perioperative morbidity was 28%. Positive margins and extrahepatic disease resection were independently associated with poor outcome. The median disease-free survival was 12 months, with no actuarial disease-free survivors at 5 years. Recurrence pattern, response to neoadjuvant chemotherapy, time to recurrence, and resection of recurrent disease were also associated with outcome.

Conclusions

Long-term survival can be achieved after resection of multiple colorectal metastases; however, because most patients will experience recurrence of disease, effective adjuvant therapy and close follow-up is necessary.
Literatur
1.
2.
Zurück zum Zitat Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Br J Surg 1997; 84:977–80PubMedCrossRef Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Br J Surg 1997; 84:977–80PubMedCrossRef
3.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2355–42CrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2355–42CrossRef
4.
Zurück zum Zitat Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2:285–8PubMed Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2:285–8PubMed
5.
Zurück zum Zitat Fong Y, Fortner J, Sun R, Brennan M, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–30PubMedCrossRef Fong Y, Fortner J, Sun R, Brennan M, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–30PubMedCrossRef
6.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection bases on 1588 patients. Assoc Fr Chirurgie. Cancer 1996; 77:1254–62 Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection bases on 1588 patients. Assoc Fr Chirurgie. Cancer 1996; 77:1254–62
7.
Zurück zum Zitat Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef
8.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRef Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRef
9.
Zurück zum Zitat De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed
10.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30PubMedCrossRef Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30PubMedCrossRef
11.
Zurück zum Zitat Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291–9PubMedCrossRef Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291–9PubMedCrossRef
12.
Zurück zum Zitat Bolton J, Fuhrman G. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231:743–51PubMedCrossRef Bolton J, Fuhrman G. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231:743–51PubMedCrossRef
13.
Zurück zum Zitat Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46(10 suppl):S22–31PubMed Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46(10 suppl):S22–31PubMed
14.
Zurück zum Zitat Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727–31PubMedCrossRef Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727–31PubMedCrossRef
15.
Zurück zum Zitat Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989; 210:127–38PubMedCrossRef Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989; 210:127–38PubMedCrossRef
16.
Zurück zum Zitat Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131:322–9PubMed Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131:322–9PubMed
17.
Zurück zum Zitat Weber S, Jarnagin W, DeMatteo R, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7:643–50PubMedCrossRef Weber S, Jarnagin W, DeMatteo R, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7:643–50PubMedCrossRef
18.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg 2002; 236:397–407PubMedCrossRef Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg 2002; 236:397–407PubMedCrossRef
19.
Zurück zum Zitat Couinaud C. Bases anatomiques des hepatectomies gauche et droite reglees. J Chir 1954; 70:933–66 Couinaud C. Bases anatomiques des hepatectomies gauche et droite reglees. J Chir 1954; 70:933–66
20.
Zurück zum Zitat Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235:803–13PubMedCrossRef Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235:803–13PubMedCrossRef
21.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–16PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–16PubMedCrossRef
22.
Zurück zum Zitat Ercolani G, Grazi G, Ravaioli M, et al. Liver resection for multiple colorectal metastases. Arch Surg 2002; 137:1187–92PubMedCrossRef Ercolani G, Grazi G, Ravaioli M, et al. Liver resection for multiple colorectal metastases. Arch Surg 2002; 137:1187–92PubMedCrossRef
23.
Zurück zum Zitat Imamura H, Seyama Y, Kokudo N, et al. Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery 2003; 135:508–17CrossRef Imamura H, Seyama Y, Kokudo N, et al. Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery 2003; 135:508–17CrossRef
24.
Zurück zum Zitat Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Ann Surg 2000; 231:487–99PubMedCrossRef Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Ann Surg 2000; 231:487–99PubMedCrossRef
25.
Zurück zum Zitat Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715–24PubMedCrossRef Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715–24PubMedCrossRef
26.
Zurück zum Zitat Tanaka K, Shimada H, Fujii Y, et al. Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbecks Arch Surg 2004; 389:371–9PubMedCrossRef Tanaka K, Shimada H, Fujii Y, et al. Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbecks Arch Surg 2004; 389:371–9PubMedCrossRef
27.
Zurück zum Zitat Cady B, Jenkins RL, Steele GD, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227:566–71PubMedCrossRef Cady B, Jenkins RL, Steele GD, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227:566–71PubMedCrossRef
28.
Zurück zum Zitat Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988; 103:278–88 Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988; 103:278–88
29.
Zurück zum Zitat Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052–64PubMedCrossRef Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052–64PubMedCrossRef
30.
Zurück zum Zitat DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal metastases. J Gastrointest Surg 2000; 4:178–84PubMedCrossRef DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal metastases. J Gastrointest Surg 2000; 4:178–84PubMedCrossRef
31.
Zurück zum Zitat Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11:274–80PubMedCrossRef Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11:274–80PubMedCrossRef
32.
Zurück zum Zitat Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90:963–9PubMedCrossRef Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90:963–9PubMedCrossRef
Metadaten
Titel
Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy
verfasst von
Peter Kornprat, MD
William R. Jarnagin, MD, FACS
Mithat Gonen, PhD
Ronald P. DeMatteo, MD, FACS
Yuman Fong, MD, FACS
Leslie H. Blumgart, MD, FACS, FRCS
Michael D’Angelica, MD, FACS
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9068-y

Weitere Artikel der Ausgabe 3/2007

Annals of Surgical Oncology 3/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.